An observational study in Chronic Inflammatory Rheumatic Diseases of Childhood, Juvenile-Onset Chronic Inflammatory Rheumatic Diseases and Transition of Care in Chronic Inflammatory Rheumatic Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rheumatic Diseases with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Rheumatic Diseases · France.
Among the 25 studies in Rheumatic Diseases with a site in France, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 25th registered.
264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.
Browse Rheumatic Diseases studies →8 of the 25 studies in Rheumatic Diseases with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
University Hospital, Brest · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 50 is below the median of 225 across 90 observational studies indexed under Rheumatic Diseases.
Median enrollment 123 across the 10 interventional studies, 397 across the 15 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 25 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 4 studies filed under Rheumatic Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Rheumatic Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07005804Lille Catholic UniversityCalcium Pyrophosphate Deposition (CPPD) Disease | 2027-05 |
| NCT07469787Assistance Publique - Hôpitaux de ParisCompassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology | 2027-08-26 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Rheumatic Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited.
Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only.
The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adult care. The primary objective is to compare transition readiness, assessed using the validated French version of the Transition Readiness Assessment Questionnaire (TRAQ-FR), between patients who received a TPE workshop plus a transition consultation and those who received a transition consultation only.
Secondary objectives include evaluating continuity of care after transition, identifying factors associated with successful transition, assessing the contribution of the RESRIP support network, and describing patients who did not benefit from structured transition support.
The transition from pediatric to adult healthcare services represents a vulnerable period for adolescents and young adults with chronic inflammatory rheumatic diseases (CIRD). This phase is associated with increased risks of poor treatment adherence, disruption of follow-up, and adverse disease outcomes. While structured transition programs have been shown to improve patient autonomy and continuity of care, evidence in rheumatology remains limited, particularly regarding real-life effectiveness after transfer to adult care.
At Bicêtre University Hospital (AP-HP, France), a structured transition program has been progressively implemented since 2018 in collaboration with adult rheumatology and internal medicine departments. This program includes early transition information, progressive empowerment, a therapeutic patient education (TPE) workshop (MIRAJE program), and a joint pediatric-adult transition consultation. In parallel, some patients benefit from additional educational and administrative support provided by the RESRIP network after transition.
The BOOST-R study is a monocentric, observational, non-interventional study conducted in the pediatric rheumatology department of Bicêtre University Hospital. Adult patients with a diagnosis of CIRD who were followed in pediatric rheumatology and participated in a joint pediatric-adult transition consultation between 2018 and 2024 are eligible. Patients are contacted by postal mail and invited to complete an online questionnaire after receiving study information and having the opportunity to express non-opposition.
The primary outcome is transition readiness assessed using the French validated 20-item Transition Readiness Assessment Questionnaire (TRAQ-FR). The primary analysis compares the mean total TRAQ-FR score between patients who benefited from a TPE workshop plus a transition consultation and those who received a transition consultation only. Higher TRAQ-FR scores indicate better self-management and readiness for adult care.
Secondary outcomes include indicators of continuity of care after transition, such as number of adult care visits, delay to first adult visit, treatment adherence, and disease flares. Additional analyses will explore demographic, clinical, social, and educational factors associated with successful transition, evaluate the impact of support by the RESRIP network, and describe patients who did not benefit from structured transition interventions.
Statistical analyses will include descriptive analyses and multivariable regression models adjusted for relevant confounders, including age, sex, underlying disease, socio-professional status, and time since transition. Sensitivity analyses using propensity score methods will be performed to account for the non-randomized design.
The study involves no intervention and no additional risk for participants. Data are collected and managed in accordance with applicable French and European data protection regulations.
Young adults with a diagnosis of chronic inflammatory rheumatic disease previously followed in pediatric rheumatology, who transitioned to adult care after participating in a joint pediatric-adult transition consultation at Bicêtre Hospital between 2018 and 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score
Total score of the Transition Readiness Assessment Questionnaire - French version (TRAQ-FR). The TRAQ-FR is a validated self-administered questionnaire assessing transition readiness in adolescents and young adults with chronic disease. It includes 20 items rated on a 5-point Likert scale (1-5). The total score is calculated as the mean of completed items. Score range: 1 to 5. Higher scores indicate greater transition readiness (better outcome).
Time frame: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)
Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Domain Scores
Domain-specific scores of the TRAQ-FR, including: Medication management, Appointment keeping, Tracking health issues, Communication with healthcare providers, Managing daily activities, Each domain score is calculated as the mean of completed items within that domain. Score range for each domain: 1 to 5. Higher scores indicate greater transition readiness.
Time frame: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care within 12 months after transition
Proportion of patients who attended at least one adult specialist consultation within 12 months after their last pediatric visit. Unit of measure: Percentage (%). Higher percentage indicates better continuity of care.
Time frame: 12 months after transition
TRAQ-FR Total Score according to participation in structured transition support programs
Comparison of TRAQ-FR total score between patients who participated in a structured transition support program (therapeutic patient education and/or structured support network) and those who did not. Score range: 1 to 5. Higher scores indicate greater transition readiness.
Time frame: Baseline (at the time of questionnaire completion in 2026)
Continuity of adult care according to participation in structured transition support programs
Proportion of patients attending at least one adult specialist consultation within 12 months after transition, compared between patients with and without structured transition support. Unit of measure: Percentage (%).
Time frame: 12 months after transition
Successful transition defined by TRAQ-FR total score ≥4
Proportion of patients with a TRAQ-FR total score ≥4, considered indicative of high transition readiness. Unit of measure: Percentage (%). Higher percentage indicates more successful transition.
Time frame: Baseline (at the time of questionnaire completion in 2026)
Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.
Of 37 observational studies under Rheumatic Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 14. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →